Zhongshan Daxue xuebao. Yixue kexue ban, 1999 目的:探讨慢性乙型肝炎血清透明质酸(HA)和抗-HBe 与肝组织病理改变的关系。方法: 对 170 例慢性乙型肝 炎患者进行肝活检,观察肝组织病理分级( G)和分期( S)情况, 同时检测 HA 及肝炎病毒标志物。 结果:①血清 HA 与肝组织病 理分级和分期关系密切,随着病理分级和分期的升高,HA 也逐渐升高,G4、S4 的血清 HA 分别比 G1、S1 显著升高(P
doaj
[Research progress on the multidimensional regulation of gut microbiota on metabolism, immunity, and inflammatory response in metabolic associated fatty liver disease]. [PDF]
Zhonghua Gan Zang Bing Za ZhiWu ST, Lu XL.
europepmc +1 more source
Zhongshan Daxue xuebao. Yixue kexue ban, 1995 对１２８例有病理诊断依据的肝细胞场（ＨＣＣ）、４７例慢迁肝（ＣＰＨ）、１０５例慢活肝（ＣＡＨ）、４６例肝硬化（ＬＣ）．采用嵌套式ＰＣＲ技术检测其血标本中的丙型肝炎病毒（ＨＣｖ）ＲＮＡ和乙型肝炎病毒（ＨＢＶ）ＤＩＩＡ，对这两种病毒的血清学标志也进行了研究。结果：在ＨＣＣ组。ＨＣＶＲＮＡ１４．１％阳性，ＨＢＶＤＮＡ７ｉ．３％阳性。ＣＰＨ，ＣＡＨ，ＬＣ和ＨＣＣ的ＨＢＶ感染率均在９０％左右，而ＨＣＶ感染率则分别为８．５％、９．５％、１７．４％和１９．５％，显示ＨＣＶ感染率随肝病严重程度的增加而有增加的趋势 ...
doaj
[Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B]. [PDF]
Zhonghua Gan Zang Bing Za ZhiWang ZW +11 more
europepmc +1 more source
[Reflections on the novel definition and whether or not antiviral therapy for inactive HBsAg carrier state in the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)"]. [PDF]
Zhonghua Gan Zang Bing Za ZhiRen S, Zheng SJ, Chen XY.
europepmc +1 more source
[Advances in research on metabolic associated fatty liver disease in 2025]. [PDF]
Zhonghua Gan Zang Bing Za ZhiRao HY, Zhao JM, Yu CH, Mi YQ, Wei L.
europepmc +1 more source
[Research progress in the field of liver failure with artificial livers in 2025]. [PDF]
Zhonghua Gan Zang Bing Za ZhiHan T.
europepmc +1 more source
C型慢性肝炎患者に対するインターフェロンとリバビリンの併用療法におけるアドヒアランスに関連する因子の検討：患者の治療意欲と医師の治療経験の重要性 [PDF]
, 2009 Tanioka, Daisuke
core
[Research progress on serum chitinase-3-like protein 1 for diagnosing early-stage liver fibrosis non-invasively]. [PDF]
Zhonghua Gan Zang Bing Za ZhiLi XN, Wang B.
europepmc +1 more source